The EPA is calling for informationon the use of fluazinam in Aotearoa New Zealand. Some of the commonly named products containing fluazinam are: Gem fungicide Nando Ohayo 500 SC Preguard Agpro Fluazinam 500 Pinnacle Curalan Flick 500 SC Fungicide Nexus Florid Nexigro Apex This is an opportunity for you, as interested parties and/or stakeholders, to provide information on fluazinam-containing substances that are available in Aotearoa New Zealand, and how those substances are used. We are looking for any relevant information industry, users, other interested parties or the public can provide to us relating to the current use, practices, and benefits of fluazinam substances. This includes any information relating to the effects of the substances, positive or adverse; toxicology; ecotoxicology; environmental fate studies; or monitoring results. We particularly request data that relates to dermal absorption, acceptable operator exposure limits, risks to aquatic organisms and risks to soil-dwelling organisms. As the current risk management framework is driven to a large extent by industry requirements, we want to better our understanding of current industry requirements, such as: -the identification and nature of the risks being managed -what measures are implemented to manage risks -the effectiveness of the current requirements in managing risks to human health and the environment -how the industry requirements align with other regulatory requirements under different pieces of legislation (eg Hazardous Substances and New Organisms Act 1996, Health and Safety at Work Act 2015 and Resource Management Act 1991). [b] The closing date to submit a response has been extended until Wednesday 30 November 2022.[/b] [b] Webinars for interested parties[/b] The EPA will be conducting one or more webinars in mid-October to provide further information on this call for information and the possibility of a reassessment. Please register your interest for participating in a webinar by emailing [url=mailto:reassessments@epa.govt.nz]reassessments@epa.govt.nz[/url] or by answering question 1.2. Webinars will only be held if there is sufficient interest. We are anticipating scheduling a webinar for industry, Māori, NGO’s and/or members of the public. Whether these will be one session or separate sessions will be decided based on interest levels. This will be an opportunity to learn about the fluazinam call for information and ask questions. [b] Responding to the call for information[/b] Please read the important information below which details how the information provided will be used. You are welcome to answer all of the questions or only those that are relevant to you. [b] How[/b] [b]we will use the information[/b] This information will be used to prepare an application for reassessment, to determine whether the EPA should undertake a modified or full reassessment of fluazinam, and to inform that reassessment process. Interested parties will have an opportunity to make formal submissions on our assessment and proposal once an application has been lodged. Your information may be made publicly available. We may publish or otherwise make available all or part of your response. This may include your name but not your contact details. We acknowledge that some information may be commercially sensitive or be otherwise regarded as confidential. If you believe any of the information you are providing should not be made publicly available, please clearly indicate this within your response, and give the reasons, so we can consider this before publishing any information. [b] Privacy statement                                                                                           [/b] Any personal information you supply when providing information will be used only in relation to this call for information. You have a right to access and correct any personal information held by us, by contacting the EPA at [url=mailto:info@epa.govt.nz][b]info@epa.govt.nz[/b][/url]. You may request that your personal information (such as your name) be with held from publicly available information. We will not make your personal contact details publicly available. Official Information Act. The Official Information Act 1982 (OIA) applies to all information held by the EPA (subject to section 55 of the Hazardous Substances and New Organisms Act 1996), and information may be released under the OIA unless there are grounds to withhold it. If you consider any part of your response is confidential, please clearly label it as such and include the reasons why you think the information is confidential (eg, you may consider some information to be commercially sensitive). Further information on the OIA is at [url=http://www.ombudsman.parliament.nz/][b]www.ombudsman.parliament.nz[/b][/url] Please fill in the form below, then click Continue to review your submission. At any time you may click Save and Exit so that you can return later.

You must provide either a company name or given name(s)

Part 1: Responder type
Are you representing your own views or those of an organisation that you belong to?
Which group do you belong to? Please select the category that most closely matches your role.
Are you interested in attending an EPA hosted webinar to learn more about the fluazinam call for information? You may also register interest by emailing reassessments@epa.govt.nz
Part 2: Product information and quantities
Part 3: Packaging and labelling
Part 4: Use of fluazinam products
Part 5: Mitigation measures and controls
Part 6: Impacts on Māori
Part 7: Key studies for EPA modelling
7.1 We are looking for key studies containing specific data to input into our aquatic, soil and human health risk assessments for fluazinam. This modelling has the potential to affect the reassessment outcome and the subsequent controls set for all substances containing the active ingredient. It is important that our modelling is done in a robust and comprehensive manner using the best data available. Do you hold any studies that might be relevant to a reassessment on fluazinam?
7.2 Do you hold any dermal absorption studies related to formulations containing fluazinam? Please expand below and attach at the end of your submission.
7.3 Do you hold any Dislodgeable Foliar Residue (DFR) studies/information that might allow refinements to the worker re-entry risk assessment for any particular crop/formulation combinations? Please expand below and attach at the end of your submission.
7.4 Do you hold any information related to the selection of an appropriate Acceptable Operator Exposure Limit (AOEL) for fluazinam, noting that the EPA is using the European regulators assessments as reference and that the currently listed AOEL from the EU authorities is 0.004 mg/kg bw day (based on a 52-week dog study)? Please expand below and attach at the end of your submission.
7.5 Do you hold any information that would allow the refinement of the risks to aquatic organisms and in particular sediment-dwelling invertebrates? Please expand below and attach at the end of your submission.
7.6 Do you hold any chronic toxicity sediment study on an appropriate sediment-dwelling species (Chironomus sp./Lumbriculus sp.) (OECD 219)? Please expand below and attach at the end of your submission.
7.7 Do you hold any information that would allow the refinement of the risks to soil-dwelling organisms and in particular earthworms? Please expand below and attach at the end of your submission.
Part 8: Benefits and alternatives to fluazinam products
Part 9: Hearing your views
Part 10: Confidential or commercially sensitive information